The first-in-class disease-modifying drug for chronic airway disorders

Project Information

BRONCHOTHELIN

Grant agreement ID: 947081

DOI

10.3030/947081

Project closed

EC signature date 6 May 2020

Start date 1 January 2020

End date 31 December 2021

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 578 020,00

EU contribution

€ 2 500 000,00

Coordinated by

EpiEndo Pharmaceuticals ehf
Iceland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Conference proceedings (1)

Azithromycin ameliorates sulfur dioxide-induced airway epithelial damage and inflammatory responses

Author(s): Joelsson, J.P., Kricker, J.A., Arason, A.J. et al.
Published in: Respiratory Research, Issue 21, Article no 233, 2020
Publisher: Springer Nature
DOI: 10.1186/s12931-020-01489-8

Peer reviewed articles (1)

Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development

Author(s): Jennifer A. Kricker, Clive P. Page, Fridrik Runar Gardarsson, Olafur Baldursson, Thorarinn Gudjonsson and Michael J. Parnham
Published in: Pharmacological Reviews, Issue October 2021, 73 (4), 2021, Page(s) 233-262, ISSN 0031-6997
Publisher: American Society for Pharmacology and Experimental Therapeutics
DOI: 10.1124/pharmrev.121.000300